胶质瘤流行病学与治疗模式的深度分析
基于SEER数据库44,778例胶质瘤患者(1980-2019年)数据,分析年龄、性别、种族、收入等流行病学特征及不同治疗策略对生存的影响。总体发病率呈下降趋势,白人、男性及60岁以上人群发病率较高;各亚组生存率逐渐提高。手术治疗在1-2级胶质瘤中生存率最佳;3-4级胶质瘤中手术联合化疗生存更优。Cox回归显示化疗和IDH突变是保护因素,3-4级肿瘤和年龄≥50岁是危险因素。
要点
- 胶质瘤总体发病率呈下降趋势,白人、男性及60岁以上人群发病率较高。
- 1-2级胶质瘤手术治疗生存率最佳;3-4级胶质瘤手术联合化疗生存更优。
- IDH突变和/或1p/19q共缺失患者,手术联合放化疗疗效最佳。
核心结论
- 胶质瘤发病率呈动态变化且总体下降,各亚组生存率逐渐提高。
- 分子特征(IDH突变、1p/19q共缺失)和社会经济因素具有预后价值。
- 不同治疗模式对胶质瘤生存的影响可为临床诊治策略提供依据。
研究设计与样本
- 基于SEER数据库的回顾性人群研究,纳入44,778例1980-2019年治疗的胶质瘤患者。
- 采用Kaplan-Meier法绘制生存曲线,Cox回归分析预后因素。
主要发现
- 总体发病率呈下降趋势,白人、男性及>60岁人群发病率较高。
- 各亚组生存率逐渐升高。
- 1-2级胶质瘤手术治疗生存率最佳;3-4级胶质瘤手术联合化疗生存更优。
- 术后放疗患者Cox回归显示:化疗(HR 0.386,95%CI 0.272-0.549)和IDH突变(HR 0.181,95%CI 0.097-0.335)为保护因素。
- 3-4级肿瘤(HR 2.179,95%CI 1.303-3.645)和年龄≥50岁(HR 1.746,95%CI 1.239-2.461)为危险因素。
关键数值与推荐
- 1-2级胶质瘤:手术治疗生存率最佳。
- 3-4级胶质瘤:手术联合化疗生存更优。
- IDH突变和/或1p/19q共缺失患者:手术联合放化疗疗效最佳。
临床怎么用
- 临床可根据胶质瘤级别选择手术或手术联合化疗/放化疗策略。
- IDH突变和1p/19q共缺失状态可用于指导治疗决策和预后评估。
- 年龄≥50岁和高级别肿瘤提示预后较差,需加强随访和综合治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioma is a common malignant intracranial tumor. This study investigated different treatment strategies and multiple epidemiological characteristics-including age, sex, ethnicity, and income-on the risk of developing glioblastoma and patient survival outcomes. METHODS: We obtained data from 44,778 patients treated for gliomas (1980-2019) from the Surveillance, Epidemiology, and End Results database. The survival curve was plotted using the Kaplan-Meier method, and Cox regression analysis was employed for prognostic factor analysis. RESULTS: This study analyzed the incidence and survival trends of glioma based on population data from the Surveillance, Epidemiology, and End Results database. The overall incidence rate exhibited a downward trend, with a higher incidence rate among Whites, men, and people aged >60 years. The survival rate of each subgroup gradually increased. Surgical treatment yields the best survival rates in grade 1-2 gliomas. In grade 3-4 gliomas, survival outcomes are better when treated with surgery, followed by chemotherapy. Cox regression analysis of the prognosis of patients undergoing postoperative radiotherapy revealed that chemotherapy (hazard ratio [HR], 0.386; 95% confidence interval [CI], 0.272-0.549) and isocitrate dehydrogenase mutations (HR, 0.181; 95% CI, 0.097-0.335) were protective factors, whereas grade 3-4 tumors (HR, 2.179; 95% CI, 1.303-3.645) and age ≥50 years (HR, 1.746; 95% CI, 1.239-2.461) were risk factors. For patients with isocitrate dehydrogenase mutations and/or 1p/19q codeletion, surgery combined with chemoradiotherapy offers the best therapeutic efficacy. CONCLUSIONS: These findings reveal the dynamic changes in the incidence pattern of glioma, the continuous improvement in survival rates, and the prognostic value of molecular characteristics and socioeconomic factors, deepening the understanding of the effects of different treatment modalities and providing a basis for clinical diagnosis and treatment strategies.
引用
- Ji M, Tian D, Qi Q, et al. Analytical Insights into the Epidemiology of Glioma and Treatment Modalities. World Neurosurg. 2025. PMID: 41456753. doi:10.1016/j.wneu.2025.124757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。